CDH1 rs16260: Understanding the Promoter Variant
The rs16260 variant is a well-characterized single nucleotide polymorphism located in the promoter region of the CDH1 gene. It is primarily studied for its potential to modulate transcriptional activity and its reported associations with susceptibility to various cancers.
What each genotype means
Baseline risk profile
This genotype is considered the reference or normal state for this variant in the CDH1 gene. Research indicates that individuals with this profile do not show the increased statistical association with prostate cancer risk observed in carriers of the A allele.
This is the most common genotype across most global populations.
Moderately increased risk
Carrying one copy of the A allele is associated with a 1.5 to 1.7-fold increased statistical risk of developing prostate cancer compared to those with the C/C genotype. This variant is located in the promoter region of the CDH1 gene, which may influence gene expression, though the clinical significance for individual health remains limited.
Carried by a significant portion of the population, with a minor allele frequency of approximately 0.23 globally.
Elevated risk profile
Carrying two copies of the A allele is associated with an approximately 2.6-fold increased statistical risk of developing prostate cancer compared to those with the C/C genotype. While this association has been observed in research studies, it is not a diagnostic indicator of disease; please discuss any concerns regarding cancer screening with your healthcare provider.
This genotype is less common than the heterozygous state, occurring in a smaller percentage of the population based on the minor allele frequency.
What is rs16260?
The rs16260 variant, often referred to as the -160C>A polymorphism, is a genetic change located in the promoter region of the CDH1 gene on chromosome 16. A promoter is a specific DNA sequence that acts as an on-off switch for a gene, determining how much of the gene's product is created. By sitting in this regulatory area, the rs16260 variant can influence the efficiency with which the cell machinery reads the CDH1 gene. Because this site is critical for controlling gene expression, researchers have long investigated whether the presence of the 'A' allele instead of the 'C' allele alters the amount of protein produced, potentially impacting cellular stability and tissue integrity.
The Role of the CDH1 Gene
The CDH1 gene provides instructions for making a protein called E-cadherin. This protein is a type of cell adhesion molecule, which acts like a biological glue, helping cells stick together to form organized tissues. E-cadherin is essential for maintaining the structure of epithelial tissues, which line the surfaces and cavities of the body. When E-cadherin functions correctly, it helps prevent cells from detaching and migrating, a process that is often disrupted in the development of certain cancers. Because of its role in maintaining tissue architecture, the CDH1 gene is frequently studied in the context of tumor suppression and the prevention of metastasis.
Research and Associations
Scientific literature has explored the association between rs16260 and various health outcomes, including gastric, breast, and prostate cancers. Some studies have suggested that the 'A' allele may be linked to altered transcriptional activity, which could theoretically influence cancer risk. However, the evidence strength for these associations remains limited and often inconsistent across different populations. While some early research indicated a potential increased risk for certain cancers, other studies have found no significant effect on disease progression or mucosal evolution. It is important to note that genetic associations are complex; they do not act in isolation and are influenced by environmental factors, lifestyle, and other genetic modifiers. Consequently, the clinical utility of this specific variant for individual risk prediction is currently not well-established.
What You Can Do With This Information
If you have received information about your rs16260 genotype, it is important to view it within the context of your overall health and family history. This variant is a common genetic marker, and having a particular genotype does not mean you will develop a specific condition. Because the evidence linking rs16260 to disease is limited and mixed, it is not typically used in routine clinical screening or diagnostic testing. If you are concerned about your personal or family history of cancer, the most effective step is to consult with a healthcare professional or a certified genetic counselor. They can help you interpret your results, assess your actual risk based on clinical factors, and determine if further screening or surveillance is appropriate for your specific situation.
How common is this variant?
The minor allele frequency for rs16260 is approximately 0.20 to 0.30 in European and East Asian populations according to gnomAD data.
Frequently asked questions
Is rs16260 a diagnostic test for cancer?
No, rs16260 is not a diagnostic test. It is a common genetic variant, and its presence does not confirm or rule out the development of any cancer.
Should I be worried if I have the A allele?
Having the A allele is common in the general population and does not necessarily indicate a health problem. Genetic risk is complex, and most people with this variant will never develop the conditions sometimes associated with it in research.
How does rs16260 affect E-cadherin?
The variant is located in the promoter region of the CDH1 gene, which regulates how much E-cadherin protein is produced. Researchers study it to see if it changes the efficiency of this regulation, though the clinical impact remains unclear.
Where can I get more information about my genetic risk?
If you have concerns about your health or family history, you should speak with a doctor or a genetic counselor. They can provide personalized guidance based on your medical history rather than just a single genetic marker.
Sources & further reading
Educational information only, last refreshed 9/17/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs16260?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29